Back to search
FDAFDA · Food and drugs·Recall number D-1303-2020

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, 100 count bottles, Rx Only Manufactured by: Apotex, Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326 NDC 60505-0260-1

Published June 24, 2020 · Recall initiated: May 27, 2020

Summary

FDA records drug Class II recall D-1303-2020, published June 24, 2020 and initiated May 27, 2020. Recalling firm: Apotex Inc.; Status: Completed; Reported quantity: 305,963 bottles; Lot: All lots remaining within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Apotex Inc.
Distributor
Nationwide.
Lot
All lots remaining within expiry
Risk classification
Class II
Area (FDA)
drug
Country
Canada

Related recalls

Questions about this recall

Was Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, 100 count bottles, Rx Only Manufactured by: Apotex, Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326 NDC 60505-0260-1 recalled?

Yes. FDA published recall D-1303-2020 on June 24, 2020. Reported hazard: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels

What should I do if I have this product?

Voluntary: Firm initiated · Press Release